Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell development in the artery wall, which results in narrowing, i.e., stenosis, and enlargement, i.e., aneurysm of the medium-sized arteries in the body.
This report contains market size and forecasts of Fibromuscular Dysplasia Treatment in Global, including the following market information:
Global Fibromuscular Dysplasia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Fibromuscular Dysplasia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Surgery Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Fibromuscular Dysplasia Treatment include Pfizer, Sanofi, Bayer, Merck, Novartis, Bristol-Myers Squibb, AstraZeneca, Allergan and Medtronic, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Fibromuscular Dysplasia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Fibromuscular Dysplasia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Fibromuscular Dysplasia Treatment Market Segment Percentages, by Type, 2021 (%)
Surgery Therapy
Medication
Global Fibromuscular Dysplasia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Fibromuscular Dysplasia Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Fibromuscular Dysplasia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Fibromuscular Dysplasia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Fibromuscular Dysplasia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Fibromuscular Dysplasia Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Sanofi
Bayer
Merck
Novartis
Bristol-Myers Squibb
AstraZeneca
Allergan
Medtronic
BD
Smith & Nephew
Stryker
B. Braun Melsungen
Johnson & Johnson
Hill-Rom
Alkermes Pharma Ireland
Dainippon Sumitomo Pharma